Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and ...

Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...

We can readily understand why investors are attracted to unprofitable companies. Indeed, Corbus Pharmaceuticals Holdings ( NASDAQ:CRBP) stock is up 478% in the last year, providing strong gains for ...

Shares of Corbus Pharmaceuticals Holdings Inc. CRBP rose 1.40% to $18.78 Friday, on what proved to be an all-around great ...

Corbus Pharmaceuticals Holdings ( (CRBP) ) has released its Q3 earnings. Here is a breakdown of the information Corbus Pharmaceuticals Holdings ...

Completed Enrollment of Dose Escalation Part of Phase 1 Clinical Trial of its Next-Generation Nectin-4 Targeting ADC (CRB-701 ...

Viking Therapeutics' highly anticipated weight-loss pill topped Wall Street's expectations — and a rival pill from Novo ...

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of ...

The Vallejo High School football team didn’t let the rainy weather bother its offense on Friday night en route to a 44-14 win over host De Anza. The Redhawks’ Sedrick Vaughn scored two ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Get Free Report) has received an average recommendation of “Buy” from ...